Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27104562 | 0.91 | KDM4E (0.37) | GPBAR1KDM4E | |
| SCHEMBL20224390 | 0.91 | KDM4E (0.37) | GPBAR1KDM4E | |
| SCHEMBL25000728 | 0.85 | KDM4E (0.31) | GPBAR1KDM4E | |
| SCHEMBL27104564 | 0.81 | KDM4E (0.37) | GPBAR1KDM4E | |
| SCHEMBL27422042 | 0.81 | ALDH1A1 (0.32) | — | |
| SCHEMBL20224695 | 0.80 | GPBAR1 (0.33) | GPBAR1KDM4E | |
| SCHEMBL25604120 | 0.80 | KDM4E (0.36) | KDM4E | |
| SCHEMBL25603953 | 0.77 | KDM4E (0.38) | KDM4E | |
| SCHEMBL20224631 | 0.77 | KDM4E (0.38) | GPBAR1KDM4E | |
| SCHEMBL26533468 | 0.77 | KDM4E (0.43) | GPBAR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11638760-B2 | Pyrrolobenzodiazepine antibody conjugates | MERSANA THERAPEUTICS, INC. (US) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11638760-B2 | Pyrrolobenzodiazepine antibody conjugates | GABRA4, GABRA1, GABRA2 | GPBAR1 149/4885KDM4E 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.